Evotec AG announced that a compound identified and optimized in research collaboration with Ono Pharmaceutical Co., Ltd. has been nominated to enter pre-clinical development, leading to the payment of an agreed milestone. This collaboration project was initiated in March 2008. Evotec combined high throughput screening and its proprietary fragment-based drug discovery platform to identify novel compounds active against a protease target, which were then further optimized with Ono to generate a candidate suitable for pre-clinical development.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,256 JPY | +1.44% | +1.08% | -10.35% |
06-11 | Ono Pharmaceutical Closes Deciphera Deal for About $2.4 Billion | DJ |
06-11 | Deciphera Pharmaceuticals Acquired by Ono Pharmaceutical for $2.4 Billion | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.35% | 6.67B | |
+26.12% | 45.33B | |
+38.49% | 25.36B | |
+26.90% | 16.7B | |
+20.34% | 14.59B | |
+71.05% | 14.26B | |
-0.05% | 6.79B | |
+13.07% | 5.62B | |
-8.87% | 5.73B | |
+35.45% | 5.02B |
- Stock Market
- Equities
- 4528 Stock
- News Ono Pharmaceutical Co., Ltd.
- Evotec AG Announces Collaboration with Ono Pharmaceutical Co., Ltd. in Drug Discovery